3rd Quarter - Report

GREATER NEW YORK HOSPITAL ASSOCIATION for GREATER NEW YORK HOSPITAL ASSOCIATION

Firm
Client
Income
—
Expenses
$600,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

Discussed post-hurricane disaster response by the group purchasing industry, and related efforts to bring needed supplies and drugs to providers in Puerto Rico.

LobbyistCovered position, as disclosed
LEE H PERLMAN —
AISLING WARDE ZACCARELLI —

Contacted: Drug Enforcement Administration (DEA); Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Homeland Security, Dept of (DHS); Centers For Medicare and Medicaid Services (CMS); Substance Abuse & Mental Health Services Administration (SAMHSA); Environmental Protection Agency (EPA); White House Office; SENATE; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Oppose provisions contained in the Tax Cuts and Jobs Act (H.R. 1), including provisions related to private activity bonds, the individual insurance mandate repeal, executive compensation, medical deductions, education and child care exclusions, and state and local tax deductibility.

LobbyistCovered position, as disclosed
JONATHAN COOPER —
KENNETH E RASKE —
DAVID C RICH —
SETH DEAN WARSHAW New —

Contacted: Environmental Protection Agency (EPA); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); White House Office; Drug Enforcement Administration (DEA); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (115th)

Medicare/Medicaid MMM

Hospital and Medicaid issues related to repeal and replace of the Affordable Care Act (ACA), including opposition to the American Health Care Act (House), the Better Care Reconciliation Act (Senate), the Graham-Cassidy-Heller-Johnson bill, and President Trumps FY 2019 Budget Proposal. Graduate Medical Education (GME) issues, including the Resident Physician Shortage Reduction Act of 2017 (support) (H.R. 2267/S. 1301), the Opioid Workforce Act of 2018 (support) (H.R. 5818/S. 2843), and the cuts and changes to Medicare and Medicaid GME programs in President Trumps FY 2019 budget proposal (oppose). Medicaid Disproportionate Share Hospital (DSH) cuts issues, including supporting the inclusion of a DSH cut delay in the Bipartisan Budget Act of 2018 (support) (H.R. 1892) and the continuation of DSH cuts in President Trumps FY 2019 Budget Proposal (oppose). Provide comments to CMS and OMB to advocate for a delay in further use of S-10 data for allocation of the Medicare DSH uncompensated care pool. Oppose legislation and regulations that would harm the 340B Drug Discount Program, including the cuts outlined in President Trumps FY 2019 Budget Proposal. Provide comments to CMS addressing payments to off-campus hospital outpatient departments. Support legislation to reverse the cuts to the 340B Drug Discount Program in CMS Final 2017 OPPS Rule, the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support) Support Federal funding for Puerto Ricos Medicaid program and for Medicaid for individuals and families displaced by hurricanes. Oppose legislation that would harm Medicaid GME programs including the Medicaid Graduate Medical Education Transparency Act (oppose). Support legislation to repeal the Medicaid IMD exclusion, the Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act (support) (H.R. 5797), and support the inclusion of the legislation in the SUPPORT for Patients and Communities Act (support) (H.R. 6) and the Opioid Crisis Response Act of 2018 (support) (S. 2680). Support the inclusion of legislation to increase GME funding, the Opioid Workforce Act of 2018 (support) (H.R. 5818/S. 2843), in the SUPPORT for Patients and Communities Act (support) (H.R. 6) and the Opioid Crisis Response Act of 2018 (support) (S. 2680). Oppose 340B provisions and site-neutral provisions in the CMS OPPS proposed rule for 2019.

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); SENATE; Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS); Centers For Disease Control & Prevention (CDC); White House Office; Environmental Protection Agency (EPA); Health Resources & Services Administration (HRSA); Substance Abuse & Mental Health Services Administration (SAMHSA)

Bills named: H.R. 1892 (115th), H.R. 6 (115th), H.R. 2267 (115th), H.R. 5818 (115th), S. 2680 (115th), H.R. 4392 (115th), H.R. 6071 (115th), H.R. 5797 (115th), S. 2843 (115th), S. 1301 (115th)

Budget/Appropriations BUD

Hospital and Medicaid issues related to repeal and replace of the Affordable Care Act (ACA), including opposition to the American Health Care Act (House), the Better Care Reconciliation Act (Senate), the Graham-Cassidy-Heller-Johnson bill, and President Trumps FY 2019 Budget Proposal. Oppose President Trumps FY 19 budget proposal (Efficient, Effective, Accountable: An American Budget), and it funding cuts and reforms to Federal GME programs, Medicaid uncompensated care pools, hospital outpatient departments, bad debt payments, and other hospital related provisions. The Bipartisan Budget Act of 2018 (H.R. 1892) (support) and specific hospital related provisions in the legislation, including increased funding for the National Institutes of Health (NIH) (support), disaster relief funding and increased Medicaid funding for Puerto Rico and the US Virgin Islands (support), and the inclusion of the cut to Medicare payments for hospitals that discharge patients to hospice care (oppose). Oppose House Republicans FY 2019 budget proposal (A Brighter American Future), and its funding cuts and reforms to Medicaid and Medicare, proposed reforms to federal GME programs, and efforts to repeal the Affordable Care Act (ACA). Support for provisions related to medical malpractice reform. Oppose the inclusion of language that would amend the National Organ Transplant Act in the Labor-HHS appropriations bill (H.R. 6157).

LobbyistCovered position, as disclosed
JONATHAN COOPER —
KENNETH E RASKE —
DAVID C RICH —
SETH DEAN WARSHAW New —

Contacted: Health Resources & Services Administration (HRSA); SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); White House Office; HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Environmental Protection Agency (EPA); Drug Enforcement Administration (DEA)

Bills named: H.R. 6157 (115th), H.R. 1892 (115th)

Insurance INS

The Childrens Health Insurance Program, including the reauthorization of the program in the January 2018 continuing resolution to fund the Federal government (support) (H.R. 195) and the extension of the program in the Bipartisan Budget Act of 2018 (support) (H.R. 1892). Support legislation to repeal the Medicaid IMD exclusion, the Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act (support) (H.R. 5797), and support the inclusion of the legislation in the SUPPORT for Patients and Communities Act (support) (H.R. 6) and the Opioid Crisis Response Act of 2018 (support) (S. 2680).

LobbyistCovered position, as disclosed
JONATHAN COOPER —
KENNETH E RASKE —
DAVID C RICH —
SETH DEAN WARSHAW New —

Contacted: Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC); SENATE; White House Office; Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES; Substance Abuse & Mental Health Services Administration (SAMHSA)

Bills named: S. 2680 (115th), H.R. 1892 (115th), H.R. 195 (115th), H.R. 6 (115th), H.R. 5797 (115th)

Immigration IMM

Oppose parts of the Executive Order (Protecting the Nation from Foreign Terrorists Entry into the United States) with a focus on its impact on residency training and teaching hospitals. Provided comments regarding the suspension of the H1-B visa Premium Processing program. Acted as a fact witness and amicus in legal challenges to the Trump Administrations executive order (Protecting the Nation for Foreign Terrorists Entry into the United States).

LobbyistCovered position, as disclosed
LAURA ALFREDO —
JONATHAN COOPER —
TIM JOHNSON —
KENNETH E RASKE —
DAVID C RICH —

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); Drug Enforcement Administration (DEA); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Homeland Security, Dept of (DHS); Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; Centers For Disease Control & Prevention (CDC); Environmental Protection Agency (EPA); Food & Drug Administration (FDA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Pharmacy PHA

Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline and local anesthetic shortages. Oppose legislation that would harm the 340B Drug Discount Program for safety net hospitals and support legislation to prevents the implementation of the cuts in CMS Final 2017 OPPS Rule (CMS-2017-0091), the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support). Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Supported legislation to increase competition in the drug marketplace and prevent REMS abuses, the CREATES Act (S. 974/H.R.2214) (support). Raise awareness about generic injectable opioid shortages, urge engagement by the Food & Drug Administration Office of Drug Shortages and approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply. Submitted comments to DEA urging the revision of its quota allocation process to recognize the unique institutional needs for injectable opioids. Submitted comments to DEA opposing proposed aggregate quota reductions for CY 2018 Schedule II controlled substances.

LobbyistCovered position, as disclosed
JONATHAN COOPER —
LEE H PERLMAN —
KENNETH E RASKE —
DAVID C RICH —
AISLING WARDE ZACCARELLI —
SETH DEAN WARSHAW New —

Contacted: Environmental Protection Agency (EPA); White House Office; Drug Enforcement Administration (DEA); SENATE; Health Resources & Services Administration (HRSA); Homeland Security, Dept of (DHS); Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Substance Abuse & Mental Health Services Administration (SAMHSA)

Bills named: H.R. 4392 (115th), S. 974 (115th), H.R. 2214 (115th), S. 124 (115th), H.R. 6071 (115th)

Health Issues HCR

Hospital and Medicaid issues related to repeal and replace of the Affordable Care Act (ACA), including opposition to The American Health Care Act (House), the Better Care Reconciliation Act (Senate) (H.R. 1628), the Graham-Cassidy-Heller-Johnson bill, and the Trump Administration's FY 2019 budget proposal. Organ donation issues, including the liver transplant allocation system and in support of new proposed UNOS system. Discussions with HHS and DHS regarding cybersecurity issues. Advocated for individual marketplace stabilization measures, including the funding of ACA cost sharing reduction payments in standalone legislation and in FY 2018 funding legislation. Graduate Medical Education (GME) issues, including the Resident Physician Shortage Reduction Act of 2017 (support) (H.R. 2267/S. 1301), the Opioid Workforce Act of 2018 (support) (H.R. 5818/S. 2843), and the cuts and changes to Medicare and Medicaid GME programs in President Trumps FY 2019 budget proposal (oppose). Support the inclusion of legislation to increase GME funding, the Opioid Workforce Act of 2018 (support) (H.R. 5818/S. 2843), in the SUPPORT for Patients and Communities Act (support) (H.R. 6) and the Opioid Crisis Response Act of 2018 (support) (S. 2680). Support legislation to repeal the Medicaid IMD exclusion, the Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act (support) (H.R. 5797), and support the inclusion of the legislation in the SUPPORT for Patients and Communities Act (support) (H.R. 6) and the Opioid Crisis Response Act of 2018 (support) (S. 2680). Support legislation to align 42 CFR Part 2 regulations with the Health Insurance Portability and Accountability Act (HIPAA), The Overdose Prevention and Patient Safety Act (support) (H.R. 6082), and support the inclusion of the legislation in the SUPPORT for Patients and Communities Act (support) (H.R. 6) and the Opioid Crisis Response Act of 2018 (support) (S. 2680). Support the SUPPORT for Patients and Communities Act (support) (H.R. 6). Support the Opioid Crisis Response Act of 2018 (support) (S. 2680). Lobby HHS, HRSA, OPTN and UNOS on liver allocation reforms. Support liver allocation reforms, including the Fairness in Liver Allocation Act (support) (H.R. 6517). Oppose legislation to amend the National Organ Transplant Act, the National Organ Transplant Act Amendments of 2018 (oppose) (H.R. 6458), and the inclusion of language that would amend the National Organ Transplant Act in the Labor-HHS appropriations bill (H.R. 6157). Oppose 340B provisions and site-neutral provisions in the CMS OPPS proposed rule for 2019.

Contacted: Health & Human Services, Dept of (HHS); Homeland Security, Dept of (DHS); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Substance Abuse & Mental Health Services Administration (SAMHSA); White House Office; SENATE; Environmental Protection Agency (EPA); Drug Enforcement Administration (DEA); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC)

Bills named: S. 2680 (115th), H.R. 6082 (115th), H.R. 6458 (115th), H.R. 6517 (115th), S. 1301 (115th), H.R. 1628 (115th), S. 2843 (115th), H.R. 5797 (115th), H.R. 5818 (115th), H.R. 6157 (115th), H.R. 2267 (115th), H.R. 6 (115th)

Affiliated organisations

OrganisationLocation
ACURITY, INC. NEW YORK, NY, US
GNYHA MANAGEMENT CORPORATION NEW YORK, NY, US
GNYHA VENTURES, INC. NEW YORK, NY, US

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.